EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials

Xin Hui S Chan, Ilsa L Haeusler, Bennett J K Choy, Md Zakiul Hassan, Junko Takata, Tara P Hurst, Luke M Jones, Shanghavie Loganathan, Elinor Harriss, Jake Dunning, Joel Tarning, Miles W Carroll und 2 weitere

The Lancet Microbe · 2025-05 · 6 (5) · 101002

DOI: 10.1016/j.lanmic.2024.101002 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Lancet Microbe, 2025-05. Verfasst von Xin Hui S Chan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pandemic Sciences Institute Nuffield Department of Medicine, University of Oxford, Oxford, UK; Centre for Tropical Medicine and Global Health Nuffiel…. Hauptthemen laut MEDLINE: Henipavirus Infections, Nipah Virus, Antiviral Agents. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Bill and Melinda Gates Foundation, Foreign, Commonwealth and Development Office.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nipah virus disease is a bat-borne zoonosis with person-to-person transmission, a case-fatality rate of 38-75%, and well recognised potential to cause a pandemic. The first reported outbreak of Nipah virus disease occurred in Malaysia and Singapore in 1998, which has since been followed by multiple outbreaks in Bangladesh and India. To date, no therapeutics or vaccines have been approved to treat Nipah virus disease, and only few such candidates are in development. In this Review, we aim to assess the safety and efficacy of the therapeutic options (monoclonal antibodies and small molecules) for Nipah virus disease and other henipaviral diseases to support prioritisation of drug candidates for further evaluation in clinical trials. At present, sufficient evidence exists to suggest trialling 1F5, m102.4, and remdesivir (alone or in combination) for prophylaxis and early treatment of Nipah virus disease. In addition to well designed clinical efficacy trials, in-vivo pharmacokinetic-pharmacodynamic studies are needed to optimise the selection and dosing of therapeutic candidates in animal challenge and natural human infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Henipavirus InfectionsNipah VirusAntiviral AgentsHumansAnimalsClinical Trials as TopicAntibodies, MonoclonalAdenosine MonophosphateAlanine

Substanzen

Antiviral AgentsAntibodies, MonoclonalremdesivirAdenosine MonophosphateAlanine

Autor:innen und Institutionen

  • Pandemic Sciences Institute Nuffield Department of Medicine, University of Oxford, Oxford, UK; Centre for Tropical Medicine and Global Health Nuffield Department of Medicine, University of Oxford, Oxford, UK; Department…
  • Pandemic Sciences Institute Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Pandemic Sciences Institute Nuffield Department of Medicine, University of Oxford, Oxford, UK; International Severe Acute Respiratory and Emerging Infection Consortium University of Oxford, Oxford, UK; Programme for Eme…
  • Department of Clinical Infection, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Pandemic Sciences Institute Nuffield Department of Medicine, University of Oxford, Oxford, UK; Centre for Human Genetics Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Academic Foundation Programme, Kent Surrey and Sussex Deanery, London, UK.

Förderung

  • Wellcome Trust
  • Bill and Melinda Gates Foundation
  • Foreign, Commonwealth and Development Office
  • National Institute for Health and Care Research
  • National Institute for Health Research Health Protection Research Unit

Zitieren

APA

Chan, X. H. S., Haeusler, I. L., Choy, B. J. K., Hassan, M. Z., Takata, J., Hurst, T. P., Jones, L. M., Loganathan, S., Harriss, E., Dunning, J., Tarning, J., Carroll, M. W., Horby, P. W., & Olliaro, P. L. (2025). Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials. The Lancet Microbe, 6(5), 101002. https://doi.org/10.1016/j.lanmic.2024.101002

Vancouver

Chan XHS, Haeusler IL, Choy BJK, Hassan MZ, Takata J, Hurst TP, et al. Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials. The Lancet Microbe. 2025;6(5):101002. doi:10.1016/j.lanmic.2024.101002

BibTeX
@article{Chan2025,
  author = {Chan, Xin Hui S and Haeusler, Ilsa L and Choy, Bennett J K and Hassan, Md Zakiul and Takata, Junko and Hurst, Tara P and Jones, Luke M and Loganathan, Shanghavie and Harriss, Elinor and Dunning, Jake and Tarning, Joel and Carroll, Miles W and Horby, Peter W and Olliaro, Piero L},
  title = {Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials},
  journal = {The Lancet Microbe},
  year = {2025},
  volume = {6},
  number = {5},
  pages = {101002},
  doi = {10.1016/j.lanmic.2024.101002}
}
Kostenlos starten →